A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction

Trial Profile

A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Dabrafenib (Primary)
  • Indications Renal failure; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jan 2016 Planned number of patients changed from 6 to 122 as per ClinicalTrials.gov record.
    • 06 Jan 2016 Planned number of patients changed from 6 to 122 as per ClinicalTrials.gov record.
    • 17 Dec 2015 Planned number of patients changed from 122 to 6 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top